BioSpace

Escolta'l a la teva aplicació

• Apple Podcasts
• Pocket Casts
• Castro
• Podcast Index
• RSS

Episodis

281 episodis

1. Beyond the needle: The future of intratumoral therapy fa 3 dies 21:02
2. Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review fa 4 dies 23:00
3. Stability, speed and strategy: Inside Australia’s early‑stage edge fa 1 setmana 21:19
4. Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 fa 2 setmanes 23:34
5. Why investors are taking another look at kidney disease fa 2 setmanes 18:26
6. Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners fa 3 setmanes 17:49
7. Bonus: Q3 2026 Job Market Update fa 3 setmanes 16:20
8. The decisions behind scientific progress fa 3 setmanes 10:52
9. J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback fa 4 setmanes 19:48
10. Beyond equity: Why venture debt is reshaping European biotech fa 1 mes 22:35
11. Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more fa 1 mes 24:18
12. The race for access: How the FAIR Act could reclaim U.S. biotech leadership fa 1 mes 20:28
13. AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll fa 1 mes 20:09
14. How radioligand therapy is rewriting cancer care fa 1 mes 15:38
15. Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz fa 2 mesos 21:21
16. When vision fades: Rethinking wet AMD and the durability gap fa 2 mesos 21:35
17. FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival fa 2 mesos 22:11
18. The supply chain fault lines of modern pharma fa 2 mesos 36:20
19. Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease fa 2 mesos 20:19
20. Breaking borders: Building biotech scale in Benelux fa 2 mesos 18:34
21. Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals fa 2 mesos 20:23
22. Fragile X at a turning point: Breaking through the clinical bottleneck fa 2 mesos 19:23
23. Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed fa 2 mesos 23:27
24. Rewriting the rules of CMV prevention fa 3 mesos 19:39
25. Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more fa 3 mesos 19:08
26. The Italian inflection point: Clinical strength, culture and capital fa 3 mesos 18:54
27. Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight fa 3 mesos 19:01
28. Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms fa 3 mesos 23:14
29. The next treatment-resistant depression paradigm fa 3 mesos 20:18
30. Life after the lead asset: Advancing an early-stage pipeline fa 3 mesos 24:01
31. Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more fa 3 mesos 17:10
32. Nordic biotech’s next act: From fragmentation to global force fa 4 mesos 20:18
33. Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2 fa 4 mesos 21:20
34. The future of pain relief: Exploring opioid alternatives fa 4 mesos 19:11
35. Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup fa 4 mesos 21:22
36. Bonus: Q2 2026 Job Market Update fa 4 mesos 9:01
37. From sequence to scale: Gene editing’s new era in biologics manufacturing fa 4 mesos 20:41
38. Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil fa 4 mesos 17:04
39. Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water fa 4 mesos 22:54
40. The Golden Triangle and the gaps: Rethinking UK biotech fa 5 mesos 19:37
41. AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more fa 5 mesos 21:36
42. From fragile skin to living medicine: Lessons from RDEB fa 5 mesos 21:43
43. Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more fa 5 mesos 25:33
44. Portugal, Spain and the new biotech frontier fa 5 mesos 20:33
45. Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence fa 5 mesos 25:02
46. Rethinking hair loss treatment fa 5 mesos 21:45
47. ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck fa 5 mesos 27:04
48. France’s biotech ecosystem: science, capital and scale fa 5 mesos 21:00
49. Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds fa 5 mesos 24:32
50. Inside Germany’s biotech capital infrastructure and innovation engine fa 6 mesos 23:17